space space   
 

News

 2007 | 2006 | 2005 | Archived
   

Gemin X To Present at BIO-Europe 2007

-Corporate Overview Includes Targeted Cancer Programs in Development, Obatoclax and GMX1777-

Montréal, QC and Malvern, PA –November 7, 2007 –Gemin X Pharmaceuticals, Inc. announced that Mr. Fred Banti, Vice-President Corporate Development, will present a corporate overview at the BIO-Europe 2007 Partnering Conference on Tuesday November 13, 2007 at 2:45 p.m. CET at the Congress Centre in Hamburg, Germany. BIO-Europe is an international conference attended by delegates from the biotechnology, pharmaceutical and financial sectors.

About Gemin X
Gemin X Pharmaceuticals, Inc., through its wholly-owned subsidiary Gemin X Biotechnologies Inc., specializes in the discovery and development of target-based novel cancer therapeutics. Gemin X's lead product, obatoclax (GX15-070), is a small molecule, pan-inhibitor of Bcl-2 proteins and is currently in Phase 2 clinical trials. Gemin X is also developing GMX1777, a small molecule that targets cancer metabolism by a p53-independent mechanism, now in Phase 1 clinical trials. Gemin X is privately held and is located in Malvern, Pennsylvania and Montréal, Québec.

return to top